United Therapeutics

Nutrition Sciences Corp, based in Derwood, MD, is positioned at the forefront of a revolutionary breakthrough in health nutrition, harnessing over 50 years of scientific research into human DNA to create a significantly personalized approach to health. With the launch of its innovative DNA personalized nutritional system expected on August 1, 2008, the company aims to establish itself in the multi-billion dollar genetics industry while offering individuals the opportunity to customize their nutritional supplements based on their unique genetics and lifestyle. In an emerging and rapidly growing industry, Nutrition Sciences Corp empowers customers to take charge of their health by revealing potential outcomes from DNA analysis, thereby providing a proactive stance against diseases and health risks. The company encourages participation through its affiliate marketing program, allowing individuals to capitalize on the genetic revolution and strive towards financial independence. Generated from the website

Sigma-Tau Pharmaceuticals Inc, a research-based pharmaceutical company headquartered in Pomezia, Italy, is dedicated to developing medications for patients with rare diseases. With over 2,500 employees worldwide, including at its Gaithersburg location, the company's research focuses on a range of disorders such as cardiovascular disease, metabolism, oncology, and immunology. As a global leader in the pharmaceutical industry, Sigma-Tau Pharmaceuticals is committed to advancing medical treatments for underserved patient populations. Their Gaithersburg office serves as an integral part of the company's corporate headquarters, contributing to innovative research and development efforts across various therapeutic areas. Generated from their available business information

Cary Pharmaceuticals is a pharmaceutical development company based in Great Falls, VA. Led by an experienced management team and Board of Directors, the company is focused on advancing the development of QuitPak, a patented treatment for smoking cessation, and a novel catheter lock solution to prevent clot formation in catheters. The company's President, Douglas Cary, brings his expertise from Abbott Laboratories, while Carl Schwan, the CFO, has successfully led two initial public offerings that raised $80 million. Additionally, Lester Crawford, a former Commissioner of the U.S. Food and Drug Administration (FDA), serves as a Director. With its dedication to innovation and a strong leadership team, Cary Pharmaceuticals is poised to make significant contributions to the pharmaceutical industry.Generated from the website